



Value Driven HealthCare and Shared Decision Making **Athens, February 18th, 2020**

Makis Papataxiarchis

President, Pharma Innovation Forum Greece
Chairman, AmCham Pharmaceutical Committee

Reality versus wishful thinking



We support collaboration among the stakeholders designed to improve and sustain the availability of innovative health technologies addressing unmet medical needs that deliver better outcomes for patients.



We consider

We share a common goal: to make innovative technologies accessible for the benefits of patients and health systems in a timely manner

Our Perspective: What Are Key Elements of an Effective HTA system



The HTA & decision making processes should be **transparent, clear** and respect commercial data confidentiality



All relevant stakeholders should be engaged formally – submission, consultation, assessment, appraisal



Independence between evaluators, decision-makers and payers



Time bound process and clear **accountability**



Locally **applicable**, not directly translated “verbatim” across borders



All **appropriate evidence** in a value framework that reflects the unmet needs of patients and clinicians

Flexibility and opportunity for dialogue

The “How” is Important: Flexibility, Dialogue and Pragmatism to Secure Patient Access



- Opportunity for on-going dialogue during appraisal
- Solutions focused, flexible
- Willingness to explore confidential patient access schemes; innovative contracting, financial risk sharing options
- Clear and independent arbitration processes

Short- & long-term recommendations

- Governance of HTA
- Provisions for an 'Early Warning' and 'Horizon Scanning' mechanism
- Early Engagement - **Interaction between MAHs and HTA agency before assessment/review**
- **Recommendations on appeals process**
- **National and International collaboration**
- **Resourcing and expertise**
- **e-health & HTA**
- *It is recommended that the independent HTA agency/institute will publish its recommendations online through its website. The assessment reports will be used as reimbursement recommendations by the Negotiation Committee and will feed into the negotiation process, should the technology be selected to undergo the mandatory negotiation process. The outcome of the negotiation process will become publicly available, expect where confidential elements are included*
- **HTA should be unbiased, rigorous and transparent**



Value Driven HealthCare and Shared Decision Making

Athens, February 18th, 2020

Thanks for your attention!

Makis Papataxiarchis

*President, Pharma Innovation Forum Greece
Chairman, AmCham Pharmaceutical Committee*